Carmell Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Public Listing

Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed public listing of its Class A common stock. The public listing is expected to take place after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended ("Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.

About Carmell Therapeutics

Carmell Therapeutics (Carmelltm) is a regenerative medicine biotech company focused on leveraging our core platform technology, Plasma-based Bioactive Material ("PBM"). PBM is a proprietary formulation of multiple Growth Factors ("GFs") and other regenerative factors contained in allogeneic platelet-enriched plasma designed to accelerate and enhance healing in bone, skin, and other tissues, as well as stimulate hair regrowth and collagen production after severe injury, disease or aging. The platform technology of PBM is initially targeted to accelerate and enhance healing in bone applications (orthobiologics), Carmelltm believes PBM has the ability to deliver many regenerative factors in spaces like aesthetic medicine (androgenic alopecia), wound care and dental bone substitute. Carmelltm currently has two PBM product candidates in development ? a Bone Healing Accelerant ("BHA") and a Tissue Healing Accelerant ("THA"). BHA has been granted Fast Track designation by the FDA and clinical development is ongoing.

For more information, please visit www.carmellrx.com and engage with us on LinkedIn https://www.linkedin.com/company/carmell-therapeutics